Cytokinetics, Incorporated
CYTKCytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Drugs in Pipeline
21
Phase 3 Programs
7
Upcoming Catalysts
2
Next Catalyst
This month
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
Aficamten Phase 3 Est. Readout
Estimated primary completion for Aficamten trial (NCT06081894) in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy. Topline data typically follows completion by weeks to months.
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How CYTK's past catalysts played out
Standard of Care
Heart Failure
Aficamten
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Omecamtiv Mecarbil (OM)
Heart Failure
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
Obstructive Hypertrophic Cardiomyopathy (oHCM)
tirasemtiv
Amyotrophic Lateral Sclerosis (ALS)
Omecamtiv Mecarbil
Heart Failure With Reduced Ejection Fraction
Reldesemtiv
Amyotrophic Lateral Sclerosis
375 mg CK-2017357
Intermittent Claudication
Reldesemtiv 150 mg
Spinal Muscular Atrophy
25 mg Omecamtiv Mecarbil
Heart Failure With Reduced Ejection Fraction
SB-743921
Non-Hodgkin's Lymphoma
CK-3773274 (5 - 15 mg)
Hypertrophic Cardiomyopathy (HCM)
250 mg CK-2017357
Amyotrophic Lateral Sclerosis
CK-1827452 24mg and 6 mg iv infusion
Heart Failure
CK-2017357 (Part A)
Amyotrophic Lateral Sclerosis
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
CK-2017357
Amyotrophic Lateral Sclerosis
Omecamtiv Mecarbil Matrix F1 Formulation
Modified Release Oral Formulation
Riluzole 50 MG
Amyotrophic Lateral Sclerosis
CK-1827452
Heart Failure
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Standard of Care | Phase 3 | Heart Failure | - | - |
Aficamten | Phase 3 | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | - | - |
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg) | Phase 3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | - | - |
Omecamtiv Mecarbil (OM) | Phase 3 | Heart Failure | - | - |
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) | Phase 3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | - | - |
tirasemtiv | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
Omecamtiv Mecarbil | Phase 3 | Heart Failure With Reduced Ejection Fraction | - | - |
Reldesemtiv | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
375 mg CK-2017357 | Phase 2 | Intermittent Claudication | - | - |
Reldesemtiv 150 mg | Phase 2 | Spinal Muscular Atrophy | - | - |
25 mg Omecamtiv Mecarbil | Phase 2 | Heart Failure With Reduced Ejection Fraction | - | - |
SB-743921 | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
CK-3773274 (5 - 15 mg) | Phase 2 | Hypertrophic Cardiomyopathy (HCM) | - | - |
250 mg CK-2017357 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
CK-1827452 24mg and 6 mg iv infusion | Phase 2 | Heart Failure | - | - |
CK-2017357 (Part A) | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) | Phase 2 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | - | - |
CK-2017357 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Omecamtiv Mecarbil Matrix F1 Formulation | Phase 2 | Modified Release Oral Formulation | - | - |
Riluzole 50 MG | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
CK-1827452 | Phase 2 | Heart Failure | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Cytokinetics, Incorporated's drug pipeline?→
CatalystAlert tracks 21 drug candidates in Cytokinetics, Incorporated's (CYTK) pipeline across Phase 3, Phase 2. Its lead program is Standard of Care (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cytokinetics, Incorporated's next FDA catalyst?→
Cytokinetics, Incorporated's (CYTK) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CYTK biotech catalysts?→
Add CYTK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cytokinetics, Incorporated's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.